Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
Por:
Bonanno, L, Costa, C, Majem, M, Sanchez, JJ, Rodriguez, I, Gimenez-Capitan, A, Molina-Vila, MA, Vergnenegre, A, Massuti, B, Favaretto, A, Rugge, M, Pallares, C, Taron, M, Rosell, R
Publicada:
14 may 2016
Resumen:
Background: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model.
Methods: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point.
Results: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0-1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004).
Conclusions: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model.
Filiaciones:
Bonanno, L:
Ist Oncol Veneto IRCCS, Med Oncol Unit 2, Via Gattamelata 64, I-35128 Padua, Italy
Costa, C:
Pangaea Biotech, Lab Translat Oncol, Sabino de Arana 5-9, Barcelona, Spain
Majem, M:
Hosp Santa Creu & Sant Pau, Med Oncol Serv, St Antoni Maria Claret 167, Barcelona, Spain
Sanchez, JJ:
Autonomous Univ Madrid, Ciudad Univ Cantoblanco, E-28049 Madrid, Spain
Rodriguez, I:
Dexeus Univ Hosp, Dept Obstet Gynecol & Reprod, Av Sabino de Arana 5-9, Barcelona, Spain
Gimenez-Capitan, A:
Pangaea Biotech, Lab Translat Oncol, Sabino de Arana 5-9, Barcelona, Spain
Molina-Vila, MA:
Pangaea Biotech, Lab Translat Oncol, Sabino de Arana 5-9, Barcelona, Spain
Vergnenegre, A:
Hosp Cluzeau, 23 Rue Larey, Limoges, France
Massuti, B:
Gen Hosp Alicante, Med Oncol, 11 Baeza, Alicante 03010, Spain
Favaretto, A:
Ist Oncol Veneto IRCCS, Med Oncol Unit 2, Via Gattamelata 64, I-35128 Padua, Italy
Rugge, M:
Univ Padua, Cytol & Pathol, Via Gabelli 61, Padua, Italy
Pallares, C:
Hosp Santa Creu & Sant Pau, Med Oncol Serv, St Antoni Maria Claret 167, Barcelona, Spain
Taron, M:
Pangaea Biotech, Lab Translat Oncol, Sabino de Arana 5-9, Barcelona, Spain
Catalan Inst Oncol, Barcelona, Spain
Rosell, R:
Catalan Inst Oncol, Barcelona, Spain
Gold, Green Published
|